1h Free Analyst Time
The urticaria drugs market is forecasted to grow by USD 1.66 bn during 2023-2028, accelerating at a CAGR of 11.64% during the forecast period. The report on the urticaria drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of urticaria, guidelines for management of urticaria patients, and increasing approval of new drugs for urticaria.
The urticaria drugs market is segmented as below:
By Application
- Acute urticaria
- Chronic urticaria
By Type
- Antihistamines
- Anti-inflammatory agents
- Sulfones
- Biologics
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the urticaria drugs market covers the following areas:
- Urticaria drugs market sizing
- Urticaria drugs market forecast
- Urticaria drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global urticaria drugs market: Allakos Inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Meiji Holdings Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, TerSera Therapeutics LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is emergence of biologics to treat urticaria.'
According to the report, one of the major drivers for this market is the increasing prevalence of urticaria.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allakos Inc.
- Amneal Pharmaceuticals Inc.
- Aurobindo Pharma Ltd.
- Bayer AG
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson
- Meiji Holdings Co. Ltd.
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Sanofi SA
- TerSera Therapeutics LLC
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
